Sino Longitudinal Study on Cognitive Decline (SILCODE): protocol for a Chinese longitudinal observational study to develop risk prediction models of conversion to mild cognitive impairment in individuals with subjective cognitive decline
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Introduction: Understanding the biological mechanism of subjective cognitive decline (SCD) in preclinical Alzheimer’s disease (AD) and identifying those who will soon convert to mild cognitive impairment (MCI) are critical for developing appropriate strategies for early diagnosis and intervention of AD. We present the study protocol of the Sino Longitudinal Study on Cognitive Decline (SILCODE), a longitudinal observational study focusing on SCD in the context of AD. Methods and analysis: Within SILCODE, approximately 800 subjects with SCD who are between 50 and 79 years old will be recruited through standardised public advertisements or memory clinics. They will undergo extensive assessment, including clinical and neuropsychological assessments, blood sample collection for plasma beta-amyloid and ApoE genotype, urine samples collection for AD7c-NTP, and multimodal MRI scans (structural MRI, diffusion tensor imaging, resting-state functional MRI and optional task-based functional MRI) as well as optional glucose metabolism and amyloid positron emission tomography. Subjects will be contacted by telephone every 3 months and interviewed, on average, every 15 months for 5 years. The study endpoint is the development of mild cognitive impairment or dementia. Jak & Bondi’s actuarial neuropsychological method will be used for diagnosis of MCI. The least absolute shrinkage and selection operator logistic regression model followed by the sub-distribution hazard function model with death as a competing risk will be constructed to establish risk prediction models. Ethics and dissemination: The ethics committee of the Xuanwu Hospital of Capital Medical University has approved this study protocol (ID: [2017]046). The results will be published in peer-reviewed journals and presented at national and international scientific conferences. Trial registration number: NCT03370744 ; Pre-results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ashburner, J., & Friston, K. J. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.02.018 · Cited by 7,507
Finding community structure in very large networks
Clauset, A., Newman, M. E. J., & Moore, C. (2004) · Physical Review E · doi:10.1103/physreve.70.066111 · Cited by 7,390
MR diffusion tensor spectroscopy and imaging
Basser, P. J., Mattiello, J., & LeBihan, D. (1994) · Biophysical Journal · doi:10.1016/s0006-3495(94)80775-1 · Cited by 5,970
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 5×
“diagnostic criteria for sCd, MCI and dementia SCD is defined by the research criteria for pre-MCI (SCD) proposed by Jessen et al in 2014(6): (1) Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event; (2) Normal age-adjusted, gender-adjus…”
BackgroundMethodInfluentialDPARSF: a MATLAB toolbox for “pipeline” data analysis of resting-state fMRI
Yan (2010) · Frontiers in System Neuroscience · doi:10.3389/fnsys.2010.00013 · Cited by 3,475
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Jessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.001 · Cited by 3,014 · cited 3×
“Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels.”
BackgroundAltered baseline brain activity in children with ADHD revealed by resting-state functional MRI
Yu-Feng, Z., Yong, H., Chao-Zhe, Z., Qing-Jiu, C., Man-Qiu, S., Meng, L., Li-Xia, T., Tian-Zi, J., & Yu-Feng, W. (2007) · Brain and Development · doi:10.1016/j.braindev.2006.07.002 · Cited by 2,660
Regional homogeneity approach to fMRI data analysis.
Zang, Y., Jiang, T., Lu, Y., He, Y., & Tian, L. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2003.12.030 · Cited by 2,614
Defining and identifying communities in networks
Radicchi, F., Castellano, C., Cecconi, F., Loreto, V., & Parisi, D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400054101 · Cited by 2,450
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925 · cited 3×
“Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels.”
BackgroundHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 3×
“(4) Other diseases that could cause cognitive decline (eg, thyroid dysfunction, severe anaemia, syphilis, or HIV).”
BackgroundMcGaugh, J. L. (1966) · Science · doi:10.1126/science.153.3742.1351 · Cited by 1,468
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 4×
“Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels.”
BackgroundMethodInfluentialBondi, M. W., Initiative, F. T. A. D. N., Edmonds, E. C., Jak, A. J., Clark, L. R., Delano-Wood, L., McDonald, C. R., Nation, D. A., Libon, D. J., Au, R., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140276 · Cited by 772 · cited 1×
“Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels.”
BackgroundSubjective Cognitive Decline in Preclinical Alzheimer's Disease
Rabin, L. A., Smart, C. M., & Amariglio, R. E. (2017) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032816-045136 · Cited by 590 · cited 1×
“Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels.”
BackgroundImplementation of subjective cognitive decline criteria in research studies
Molinuevo, J. L., Rabin, L. A., Amariglio, R., Buckley, R., Dubois, B., Ellis, K. A., Ewers, M., Hampel, H., Klöppel, S., Rami, L., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.012 · Cited by 575 · cited 2×
“Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels.”
BackgroundAD dementia risk in late MCI, in early MCI, and in subjective memory impairment.
Jessen, F., Wolfsgruber, S., Wiese, B., Bickel, H., Mösch, E., Kaduszkiewicz, H., Pentzek, M., Riedel‐Heller, S. G., Luck, T., Fuchs, A., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.09.017 · Cited by 511
Evidence of Neuronal Compensation During Episodic Memory in Subjective Memory Impairment
Erk, S. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.80 · Cited by 147
Fernández-Blázquez, M. A., Ávila-Villanueva, M., Maestú, F., & Medina, M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150956 · Cited by 98
Wolfsgruber, S., for the AgeCoDe Study Group, Kleineidam, L., Wagner, M., Mösch, E., Bickel, H., Lϋhmann, D., Ernst, A., Wiese, B., Steinmann, S., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160407 · Cited by 94 · cited 1×
“Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels.”
BackgroundBhome, R., Huntley, J. D., Price, G., & Howard, R. J. (2019) · Cognitive Neuropsychiatry · doi:10.1080/13546805.2019.1590190 · Cited by 45
Cited by
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease
Wang, X., Huang, W., Su, L., Xing, Y., Jessen, F., Sun, Y., Shu, N., & Han, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00395-3 · Cited by 265
Self-citationChen, Y., Wang, Y., Song, Z., Fan, Y., Gao, T., & Tang, X. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101911 · Cited by 152
Altered gut microbiota in adults with subjective cognitive decline: the SILCODE study
Sheng, C., Lin, L., Lin, H., Wang, X., Han, Y., & Liu, S.-L. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210259 · Cited by 78
“SILCODE is a multicenter-based longitudinal observational study in China, mainly focusing on individuals with SCD, and also includes cognitively normal subjects, patients with MCI and AD dementia [24].”
Self-citation
Metadata
- Authors
- Li, X., Wang, X., Su, L., Hu, X., & Han, Y.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2019-07
- Volume
- 9
- Issue
- 7
- Pages
- e028188
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2962822388
- Cited by
- 106
- References
- 23
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.